Q3 2024 Moderna Inc Earnings Call Transcript
(Audio in progress) Important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. I will now turn the call over to Stéphane are trued up enough.
Good morning or good afternoon, everyone. Thank you for joining us for ourselves. We will review of our business in the fourth quarter. Jamey will present our financial results and outlook, Stephen will review our clinical programs. I will then come back and share of key priorities before Q&A.
We did a good $1.9 billion of revenue in the third quarter. Net income was $13million barrels. We ended the quarter with cash and investments of $9.2 billion. As you know, formulary and now we have been working to improve productivity in the Company in the third quarter of 2024 compared to Q1 of 2023, we reduced operating expenses by $500 million across cost of sales, R&D and SG&A. This figure excludes $1.4 billion of resizing charge in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |